The Treatment: XYWAV is an FDA-approved treatment for narcolepsy and Idiopathic Hypersomnia (IH).
Study Aims: Assess the safety and efficacy of the treatment on sleepiness, polysomnography measurements (eg, sleep stage transitions, sleep patterns, and sleep quality), daytime and nighttime symptoms, pharmacokinetics (in narcolepsy), and patient-reported outcomes including subjective sleep quality and quality of life in patients with IH or narcolepsy.
Trial Duration: 10-36 weeks
Inclusion Criteria (simplified):
- 18 to 75 years old
- Has a primary diagnosis of IH or narcolepsy (Type 1 or Type 2)
